Impact of mupirocin resistance on the transmission and control of healthcare-associated MRSA

The Journal of Antimicrobial Chemotherapy
Sarah R DeenyJulie V Robotham

Abstract

The objectives of this study were to estimate the relative transmissibility of mupirocin-resistant (MupR) and mupirocin-susceptible (MupS) MRSA strains and evaluate the long-term impact of MupR on MRSA control policies. Parameters describing MupR and MupS strains were estimated using Markov chain Monte Carlo methods applied to data from two London teaching hospitals. These estimates parameterized a model used to evaluate the long-term impact of MupR on three mupirocin usage policies: 'clinical cases', 'screen and treat' and 'universal'. Strategies were assessed in terms of colonized and infected patient days and scenario and sensitivity analyses were performed. The transmission probability of a MupS strain was 2.16 (95% CI 1.38-2.94) times that of a MupR strain in the absence of mupirocin usage. The total prevalence of MupR in colonized and infected MRSA patients after 5 years of simulation was 9.1% (95% CI 8.7%-9.6%) with the 'screen and treat' mupirocin policy, increasing to 21.3% (95% CI 20.9%-21.7%) with 'universal' mupirocin use. The prevalence of MupR increased in 50%-75% of simulations with 'universal' usage and >10% of simulations with 'screen and treat' usage in scenarios where MupS had a higher transmission probabilit...Continue Reading

References

Jul 8, 2000·Proceedings of the National Academy of Sciences of the United States of America·R M Ribeiro, S Bonhoeffer
Apr 24, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A ScanvicJ C Lucet
Oct 27, 2004·Antimicrobial Agents and Chemotherapy·Julian Gregston HurdleIan Chopra
Mar 28, 2006·Proceedings of the National Academy of Sciences of the United States of America·M C J BootsmaM J M Bonten
Nov 24, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S Harbarth
Jul 19, 2008·American Journal of Epidemiology·Ben S CooperGeoffrey M Scott
Feb 24, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Heidi S M AmmerlaanMarc J M Bonten
Aug 14, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jean B PatelJohn A Jernigan
Oct 21, 2009·Proceedings of the National Academy of Sciences of the United States of America·Laura TemimeDidier Guillemot
Dec 17, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rahul BatraJonathan D Edgeworth
Mar 2, 2010·Nature Reviews. Microbiology·Christopher M ThomasThomas J Simpson
Apr 23, 2010·The Journal of Antimicrobial Chemotherapy·Olivier GallonUNKNOWN Collège de Bactériologie Virologie Hygiène (ColBVH) Study Group
Feb 15, 2011·Infectious Disease Clinics of North America·Andie S LeeStephan Harbarth
Mar 16, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Adrian G BarnettMartin Wolkewitz
Jun 2, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andie S LeeStephan Harbarth
Oct 5, 2011·The Journal of Hospital Infection·D TalonX Bertrand
Dec 27, 2011·International Journal of Antimicrobial Agents·Ian M GouldGeorg Peters
Jan 11, 2012·International Journal of Antimicrobial Agents·Stefania StefaniFiona M Mackenzie
Jul 27, 2012·The Journal of Antimicrobial Chemotherapy·Carolyne HornerMark Wilcox
Nov 14, 2012·Antimicrobial Agents and Chemotherapy·Stephanie A FritzCarey-Ann D Burnham
Apr 25, 2013·International Journal of Medical Microbiology : IJMM·Eduardo Pérez-RothMaximiliano Alvarez-Fernández
May 31, 2013·The New England Journal of Medicine·Susan S HuangUNKNOWN AHRQ DECIDE Network and Healthcare-Associated Infections Program
Oct 23, 2013·The Journal of Hospital Infection·D J Hetem, M J M Bonten
May 20, 2014·Clinical Therapeutics·Douglas J BiedenbachMeredith Hackel
Jun 11, 2014·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·David P CalfeeDeborah S Yokoe
Aug 15, 2014·Journal of Clinical Microbiology·Andie S LeePatrice François
Sep 1, 2015·The Journal of Antimicrobial Chemotherapy·John HughesOlga Tosas Auguet

❮ Previous
Next ❯

Citations

Dec 15, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David P Calfee
Dec 1, 2015·AORN Journal·Kathy AuredenFrank Myers
Feb 26, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sarah R DeenyJulie V Robotham
Feb 26, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David J HetemMarc J M Bonten
Sep 1, 2015·The Journal of Antimicrobial Chemotherapy·John HughesOlga Tosas Auguet
May 29, 2016·The Journal of Antimicrobial Chemotherapy·Petra GastmeierFrank Schwab
Mar 9, 2018·Royal Society Open Science·Rebecca H ChisholmNicholas Geard
Jun 9, 2018·Current Infectious Disease Reports·Gregory R Madden, Costi D Sifri

❮ Previous
Next ❯

Software Mentioned

R

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

© 2021 Meta ULC. All rights reserved